At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 4,936 target
Drug / intervention
Epirubicin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
In Brief
A Phase 3 clinical trial evaluating Epirubicin, Cyclophosphamide, and 2 other interventions for Breast Cancer. Completed, enrolled 4,936 participants across 2 sites.
Detailed Summary
Trial for the optimization of risk assessment and therapy success prediction in patients with early breast cancer by the use of biomarkers in advance to therapy decision-making to personalize therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2012
First PostedJan 2013
Primary CompletionSep 2019
Study CompletionJan 2025
TodayJul 2026
First PostedJan 30, 2013
Enrollment StartMay 1, 2012
Primary CompletionSep 1, 2019
Study CompletionJan 15, 2025
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 13.4 years ago
Interventions
Epirubicindrug
Cyclophosphamidedrug
Docetaxeldrug
Paclitaxeldrug